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copies/ sample, and the whole procedure from DNA extraction to
analysis requires less than 2 hours. The positive sample can be
further quantitated by using real time PCR. We also developed real
time PCR system to measure copy number of HAV, HEV, GBV,
Adenovirus, Norovirus, Metapneumovirus, Pn. jirovecci, Toxo-
plasma, and Cryptosporidium. Analysis of 980 samples from 145
patients who underwent SCT revealed that 18% of blood/urine
samples were positive for more than one virus. Although infections
with multiple viruses were less frequent in CBT-recipient than
allogeneic BMT/PBSCT-recipients, most of the CBT-recipients
with coinfection/superinfection showed profound immunodeﬁ-
ciency. Serious virus infection such as ganciclovir-resistant CMV
infection was noted in 9 out of 40 CBT-recipients. Opportunistic
infections in CBT stem from secondary immunodeﬁciency, which
often leads to predisposition to other infections, and to indirect
consequences such as graft rejection and leukemic relapse. Mea-
sures to facilitate rapid immune reconstitution would result in
control of ongoing infection and reduce non-relapse mortality.
Donor lymphocyte infusion (DLI), although not available in CBT-
recipients, would potentially be effective for opportunistic infec-
tions. We have developed a simple method for expanding activated
donor CD4-T cells from cord blood mononuclear cells (MNCs).
CD4 T-cell function such as cytokine production, was comparable
to those of adult expanded CD4 T-cells. Infusion of CD4 T-cells
expanded from cord blood was effective for viral infections such as
drug-resistant CMV disease and Coxsackie B hemorrhagic colitis.
Aggravation of GVHD, cytopenia, or organ damage was not noted
in CD4-DLI for these patients. Preparation of expanded CD4
T-cells from engrafted MNCs with low CD4 T-cells is sometimes
challenging. We would need to decide whether CD4 T-cells
should be expanded for high risk patients or for all the recipients in
advance. CD4-DLI would serve as “the second generation DLI” in
CBT since it needs small amount of blood; stimulates various limbs
of immune system; and is associated with minimal side effects.
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STEM CELLS IN THE UMBILICAL CORD MATRIX: ISOLATION AND CHAR-
ACTERIZATION
Mark L. Weiss Kansas State University, Dept of Anatomy and Physi-
ology, Midwest Institute for Comparative Stem Cell Biology, Manhattan,
KS 66506, USA
The umbilical cord is a non-controversial source of mesenchy-
mal-like stem cells (MSCs). Work from several laboratories shows
that MSCs can be isolated from several different compartments of
the umbilical cord including the umbilical cord blood (UCB), the
amnion and amniotic ﬂuid, the perivascular compartment, etc.
Work with cells derived from Wharton’s Jelly that have been
termed umbilical cord matrix (UCM) cells will be described here.
UCM cells are plastic-adherent cells that have similar surface
phenotype, differentiation potential and physiological properties to
MSCs derived from other tissues sources such as bone marrow and
adipose tissue. Unlike MSCs derived from “adult” sources, UCM
cells have several advantages, not the least of which is that they are
collected from a fairly homogenous, young population, minimal
surgical risk to patient, etc. Several labs have demonstrated a
therapeutic potential for the UCM cells in experimental disease
models, indicating the possibly that UCM cells may substitute cell
for bone marrow derived MSCs for cellular therapy, tissue engi-
neering, and biotechnology applications. Our lab and others have
demonstrated that UCM cells have a therapeutic effect in a rodent
model of Parkinson’s disease. Work in other laboratories indicates
that UCM cells may have a rescue function in other degenerative
disease. We envision that both umbilical cord blood and mesen-
chymal cells will be commercially collected and stored in the future
for experimental research and pre-clinical work, for public and
private banking services, etc. While Standard Operating Proce-
dures (SOPs) exist for UCB banking, SOPs are yet to be developed
for clinical-grade UCM cells. Some of hurdles that have been
identiﬁed for the generation of clinical-grade UCM cells will be
discussed.
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MORPHOLOGICAL AND MOLECULAR CHARACTERIZATION OF NOVEL
POPULATION OF CXCR4 SSEA-4 OCT-4 VERY SMALL EMBRYONIC-
LIKE (VSEL) CELLS PURFIED FROM HUMAN CORD BLOOD
Mariusz Z. Ratajczak, Magda Kucia, Maciej Halasa, Marcin Wysoc-
zynski, Bogdan Machalinski Stem Cell Biology Program, James Graham
Brown Cancer Center, University of Louisville, Louisville, KY, USA and
Department of Physiopathology, Pomeranian Medical University, Szc-
zecin, Poland
Mononuclear cells (MNC) isolated from bone marrow (BM) or
cord blood (CB) contributes to organ/tissue regeneration, how-
ever, the identity of the speciﬁc cell type(s) involved remains
unknown. Recently we identiﬁed in murine BM a homogenous
population of rare (0.01% of BMMNC) Sca-1 CXCR4 lin
CD45 cells that express by RQ-PCR and immuno-histochemistry
markers of pluripotent stem cells (PSC) such as SSEA-1, Oct-4,
Nanog and Rex-1, highly express Rif-1 telomerase protein and
display several features typical for primary embryonic stem cells
such as i) a large nuclei surrounded by a narrow rim of cytoplasm,
and iii) open-type chromatin (euchromatin) that is typical for
embryonic stem cells (Leukemia 2006;20,857-869). These cells
(2-4 	m in diameter) were named very small embryonic-like
(VSEL) stem cells. We will present a new two step isolation
procedure to purify a similar population of cells from human CB,
which is based on isolation of CB mononuclear cells (CB MNC) by
hypotonic lysis and multiparameter FACS sorting. Accordingly, we
perform i) hypotonic lysis of CB to remove erythrocytes and to
enrich for CB MNC combined with ii) multiparameter sorting for
CXCR4AC133CD34linCD45 CB MNC. CB-derived
VSEL (CB-VSEL) isolated this way similarly as those isolated
from adult BM are very small (3-5 	m), possess large nuclei
containing unorganized euchromatin, express nuclear embryonic
transcription factors Oct-4 and Nanog and surface embryonic
antigen SSEA-4. VSEL do not express MHC class I and class II
antigens and are CD29, CD90 and CD105 negative. In vitro
cultures CB-VSEL are able to grow neurospheres that gave rise to
neuronal lineages (beta-III tubulin, nestin, O4, MBP,
GFAP) and cardiomyocytes (beta-myosin heavy chain, alpha-
sarcomeric actin. Based on this we conclude that CB contains
VSEL and that the majority of these CB VSEL are lost during
routine procedures employed currently for banking of CB MNC.
Thus based on our observations, new more efﬁcient methods of
CB banking are needed that will enrich/preserve these cells in CB
units during preparation before storage. Furthermore, we conclude
that CB tissue/organ regenerating potential may be much higher
than initially postulated if the proper fraction of CB MNC cells
enriched in VSEL is employed and we are currently testing this
hypothesis in animal models.
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GROWTH OF HIGH PROLIFERATIVE POTENTIAL ENDOTHELIAL COL-
ONY FORMING CELLS FROM UMBILICAL CORD BLOOD
Mervin C. Yoder and David A. Ingram Indiana University School of
Medicine, Indianapolis, IN
Adult peripheral blood has long been known to contain circulat-
ing endothelial cells. Since 1997, umbilical cord blood has been
known to contain a population of circulating cells that serve as
progenitors for the endothelial lineage (EPCs). We have deter-
mined that a rare population of cells in the umbilical cord blood
emerges upon in vitro culture that displays clonal colony forming
ability. These endothelial colony forming cells (ECFCs) are
present in adult peripheral blood as well, though vastly enriched in
term and preterm cord blood. ECFC display a hierarchy of pro-
liferative potential. Cells with the highest proliferative potential
(HPP) can replate into secondary and tertiary high proliferative
potential ECFC, but also give rise to low proliferative potential (do
not self-renew), endothelial clusters, and non-dividing mature en-
dothelial cells. HPP-ECFC display signiﬁcantly greater telomerase
activity than cells with lower proliferative potential. Cord blood
ECFC are capable of forming human vessels when implanted into
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NOD/SCID mice and inosculate with murine vessels to participate
in murine systemic blood ﬂow. While CD34CD45 cells are
enriched in hematopoietic colony forming cell activity, only
CD34CD45- cells give rise to ECFC in vitro. Recent studies
indicate that ECFC can be derived from umbilical arterial and
venous endothelial cells as well as endothelium from several other
vascular sites. Thus, umbilical cord blood and blood vessels may be
sources of cells that can be used for vascular regeneration.
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DIFFERENTIATION OF UCB-DERIVED MULTI-LINEAGE PROGENITOR
CELLS INTO RESPIRATORY EPITHELIAL CELLS
David McKenna, MD University of Minnesota, Minneapolis, MN
Umbilical cord blood (UCB) recently has been examined for the
presence of stem cells capable of differentiating into cell types
representative of all three embryonic layers. The few groups re-
porting success have typically used hepatic differentiation for dem-
onstration of endodermal potential. We report differentiation of
human UCB-derived stem cells called multi-lineage progenitor
cells, or MLPCs, into respiratory epithelial cells. Using a cell
separation medium (PrepaCyte-MLPC; BioE, Inc.) and plastic
adherence, MLPCs were isolated from UCB units (American Red
Cross Cord Blood Program) and expanded. Cultures were grown
in MSCGM (Cambrex, Inc.) prior to addition of Small Airway
Growth Medium (SAGM; Cambrex, Inc.), a maintenance medium
designed for airway epithelium. Following an 8 day culture, cells
were characterized by light microscopy, transmission electron mi-
croscopy, immunoﬂuorescence (IF), and PCR. Differentiated cells
were characterized by an epithelioid morphology with lamellar
bodies, the organelles responsible for secretion of surfactant. IF
and PCR conﬁrmed presence of protein product and mRNA of
surfactant protein C, a protein highly speciﬁc for type II cells.
UCB-derived MLPCs were isolated and expanded and then dif-
ferentiated into respiratory epithelial cells using an off-the-shelf
medium designed for maintenance of fully differentiated respira-
tory epithelial cells. To the best of our knowledge, this is the ﬁrst
time human non-embryonic stem cells have been differentiated
into type II alveolar cells. Additional studies are ongoing to further
evaluate the cells and the possibilities for therapeutic applications.
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PROGRESS IN REGENERATIVE MEDICINE USING CORD BLOOD: MES-
ENCHYMAL STEM CELL ISOLATION AND INDUCTION TO BONE AND
CARTILAGE
Tsuneo A. Takahashi, Xiaohong Zhang, Koichi Igura, Toshihide Nish-
imura, Ayako Mitsuru, Masako Hirai, Satoru Yamaguchi*, Kotaro
Yoshimura** Division of Cell Processing (CERES), The Institute of
Medical Science, The University of Tokyo, Tokyo, Japan; Cell Processing
Facility, Tokyo Cord Blood Bank, Tokyo, Japan; *Yamaguchi Hospital,
Funabashi, Chiba, Japan; **Department of Plastic Surgery, The Uni-
versity of Tokyo, School of Medicine, Tokyo, Japan
Although experimental and clinical trials using bone marrow
derived mesenchymal stem cells demonstrated promising results,
cells from other sources have also been explored. We report the
isolation, expansion and differentiation of mesenchymal stem cells
(MSCs) derived from human umbilical cord blood and compare
the results to those of MSCs derived from human bone marrow,
adipose tissue and chorionic villi of placenta. Though surface
antigens of these various MSCs did not show signiﬁcant differ-
ences, differentiation abilities were signiﬁcantly different among
these MSCs. Cord blood-derived MSCs (CB-MSCs) were isolated
from 70% of cord blood units processed within 5 hours and at least
60 ml in volume. In each case these MSCs differentiated with high
efﬁciency to chondrocyte lineages as well, or better, than those
MSCs derived from bone marrow (BM-MSCs), but adipose tissue-
derived MSCs (AD- MSCs) did not. In vivo transplantation of
CB-MSCs with scaffolds, atero-collagen for chondrocyte or
-TCP for osteocytes into nude mice resulted in generation of
chondrocyte-like tissue as well as bone. Co-culture of MSCs with
lymphocytes stimulated with phytohemagglutinin and mixed lym-
phocyte culture suppressed proliferation of stimulated lymphocytes
as well as BM-MSCs and AD-MSCs, indicating that CB-MSCs
had immune-suppressive effect. Thus, the CB-MSCs can be a
possible allogeneic cell source for regenerative medicine.
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REDUCED RISK OF LEUKEMIA RELAPSE AFTER DOUBLE UCB TRANS-
PLANTATION
Michael R. Verneris, MD University of Minnesota, Minneapolis, MN
Allogeneic hematopoietic cell transplantation (allo-HCT) is po-
tentially curative therapy for patients with high-risk or relapsed
acute leukemia. In the absence of a matched sibling donor, hema-
toipoietic progenitor cells can be obtained from either the bone
marrow (BM), peripheral blood (PB) or umbilical cord blood
(UCB) of volunteer donors. Compared to BM and PB, UCB has a
number of beneﬁts including the lack of collection risk to the
donor, the absence of donor attrition and rapid availability. UCB
also has less stringent requirements for HLA matching and in the
majority of patients a suitably matched donor can be identiﬁed.
However, the widespread applicability of UCB transplantation has
been constrained by the limited volume of blood contained in
within the umbilical cord. This small volume of blood translates
into limited numbers of mononuclear cells and CD34 progenitor
cells and the dose of these (per kg recipient body weight) is the
single most import variable for UCB outcome. Thus, UCB has
been reserved mainly for children. Recently, we have demonstrated
that the addition of a second, partially HLA matched UCB unit can
augment the cell dose; increasing both the rate and frequency of
donor engraftment in patients who would otherwise have an inad-
equate cell dose with in a single UCB unit. Interestingly, the
majority (60%) of recipients of double UCB transplantation
showed engraftment of a single UCB unit. By day 21 after trans-
plant, the second unit was not detected and presumably eradicated
due to immunological mechanisms. To date it is unknown whether
the addition of a second, partially matched UCB unit has any
impact on leukemia recurrence. We retrospectively reviewed the
outcomes of patients with acute leukemia who received myeloab-
lative conditioning chemotherapy followed by either single or
double UCB transplantation. The goal was to provide an adequate
cell dose/kg to patients. On this basis, patients received either
single (n72) or double UCB (n54) unit transplantation. Recip-
ients of two UCB units had a number of transplant related variables
which differed from single unit recipients. Not surprisingly, double
unit recipients were older and weighed more than single recipients.
There were no signiﬁcant differences between the single and dou-
ble recipient groups with respect to disease (AML vs. ALL) and
stage (CR1-2 vs. CR3-relapse). Most patients (2/3rds for each
group) were in CR1-2. The total dose of infused MNCs or CD34
cells was not different between the two groups (for double UCB
transplants this was the total of both UCB units). Two conditioning
regimens were used during the course of this study. Single unit
recipients received either TBI/Cytoxan/ATG followed by CSA/
Methylprednisone (n53) or Fludarabine/CTX/TBI followed by
CSA/MMF (n14). Recipients of double unit transplantation re-
ceived only the ﬂudarabine containing regimen. The kinetics of
engraftment and incidence of TRM were not different between the
two groups. Recipients of two UCB transplants had a signiﬁcantly
higher rate of aGVHD compared to recipients of single unit
transplantation (RR2.7, 0.01). The rate of cGVHD was not
different between recipients of single and double UCB transplan-
tation. The median follow up was 4.9 yrs (CI, 0.7-1.0) for single
unit recipients and 2 yrs (CD, 0.7-5) for double unit recipients.
Cox regression showed that the following variables were not asso-
ciated with relapse: recipient age, gender, HLA disparity, CMV
serostatus, cell dose, CD34 cell dose, CD3 cell dose, condition-
ing regimen, GVHD prophylaxis and aGVHD. However, recipi-
ents of two UCB units were less likely to experience relapse relative
to single unit recipients (RR0.4, p0.06). Subgroup analysis
showed that patients with early stage disease (CR1-2) beneﬁted
from double UCB transplant (RR0.2, p0.01). There was no
difference in relapse for the advance patients (CD3-relapse) in
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